Metformina Eg Stada Italia

Metformin, the active ingredient in Metformina Eg Stada Italia, is a biguanide presented as an oral tablet for oral use. It lowers blood glucose by improving insulin sensitivity and is indicated for adults with type 2 diabetes mellitus. The product conforms to EU pharmaceutical standards and is marketed throughout the European Union.

GNH USA supplies Metformina Eg Stada Italia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality through rigorous testing and provides regulatory documentation for importers.

Metformina Eg Stada Italia (metformin) is used to manage hyperglycaemia in disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control by lowering fasting and post‑prandial glucose levels. - Prediabetes (impaired glucose tolerance): reduces progression to overt diabetes when combined with lifestyle measures. - Polycystic ovary syndrome: helps restore ovulatory cycles by decreasing insulin resistance (off‑label but widely accepted).

Metformina Eg Stada Italia may cause a range of adverse reactions, most of which are related to the gastrointestinal system.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: may develop with long‑term therapy.

Before initiating Metformina Eg Stada Italia, several safety considerations should be reviewed.

- Renal function: assess eGFR and avoid use in severe renal impairment. - Hepatic function: monitor liver enzymes, especially in patients with existing liver disease. - Lactic acidosis risk: avoid in patients with hypoxia, severe infection, or uncontrolled heart failure. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Alcohol consumption: limit intake to reduce lactic acidosis risk. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Metformina Eg Stada Italia can interact with other medicines, altering its plasma concentration or increasing the risk of adverse events.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma levels, heightening toxicity. - Excessive alcohol: amplifies risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - NSAIDs: may impair renal function, increasing metformin accumulation. - Corticosteroids: can raise blood glucose, requiring dose adjustment.